The European medicines regulator said on Friday it will review safety information for Eisai and Biogen's Leqembi, nearly ...
The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's ...
European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for ...
Seeking Alpha on MSN7h
Biogen, Eisai Alzheimer’s drug review delayed in EUBiogen (BIIB) stock in focus as company and partner Eisai (ESALF) face delay in the EU launch of Alzheimer's drug lecanemab.
Biogen and Eisai said they believe that EC's requests can be addressed with existing information, and that no new safety signals have been identified for Leqembi. The U.S. Food and Drug Administration ...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the European Commission has asked the Committee ...
Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma ...
GlobalData on MSN4d
Eisai and Biogen’s Leqembi sBLA set for Alzheimer’s maintenance dosingThe FDA has approved the sBLA of Eisai and Biogen's LEQEMBI for maintenance dosing indicated for the early stages of ...
Biogen (BIIB) and Eisai announced an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as ...
GlobalData on MSN7d
MSD and Eisai’s LEAP gastroesophageal cancer trial sees mixed successMSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but ...
The monthly maintenance regimen, which offers a more convenient frequency than the initially approved treatment schedule for ...
Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback